پی۵۳
ارجاعات

1 2 3  GRCm38: Ensembl release 89: ENSMUSG00000059552 - Ensembl, May 2017
↑  "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
↑  "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
↑  Toufektchan, E.; Toledo, F. (2018). "The Guardian of the Genome Revisited: P53 Downregulates Genes Required for Telomere Maintenance, DNA Repair, and Centromere Structure". Cancers. 10 (5): 135. doi:10.3390/cancers10050135. PMC 5977108. PMID 29734785.
1 2 3  Surget S, Khoury MP, Bourdon JC (December 2013). "Uncovering the role of p53 splice variants in human malignancy: a clinical perspective". OncoTargets and Therapy. 7: 57–68. doi:10.2147/OTT.S53876. PMC 3872270. PMID 24379683.
↑  Read AP, Strachan T (1999). "Chapter 18: Cancer Genetics". Human molecular genetics 2. New York: Wiley. ISBN 978-0-471-33061-5.
1 2  Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S (December 1984). "Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene". The EMBO Journal. 3 (13): 3257–62. doi:10.1002/j.1460-2075.1984.tb02287.x. PMC 557846. PMID 6396087.
1 2  Isobe M, Emanuel BS, Givol D, Oren M, Croce CM (1986). "Localization of gene for human p53 tumour antigen to band 17p13". Nature. 320 (6057): 84–5. Bibcode:1986Natur.320...84I. doi:10.1038/320084a0. PMID 3456488. S2CID 4310476.
1 2  Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B (June 1991). "Identification of p53 as a sequence-specific DNA-binding protein". Science. 252 (5013): 1708–11. Bibcode:1991Sci...252.1708K. doi:10.1126/science.2047879. PMID 2047879. S2CID 19647885.
1 2  McBride OW, Merry D, Givol D (January 1986). "The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13)". Proceedings of the National Academy of Sciences of the United States of America. 83 (1): 130–4. Bibcode:1986PNAS...83..130M. doi:10.1073/pnas.83.1.130. PMC 322805. PMID 3001719.
↑  Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP (September 2005). "p53 isoforms can regulate p53 transcriptional activity". Genes & Development. 19 (18): 2122–37. doi:10.1101/gad.1339905. PMC 1221884. PMID 16131611.
↑  Ziemer MA, Mason A, Carlson DM (September 1982). "Cell-free translations of proline-rich protein mRNAs". The Journal of Biological Chemistry. 257 (18): 11176–80. doi:10.1016/S0021-9258(18)33948-6. PMID 7107651.
↑  Levine, Arnold Jay; Lane, David P., eds. (2010). The p53 family. Cold Spring Harbor Perspectives in Biology. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press. ISBN 978-0-87969-830-0.
↑  May P, May E (December 1999). "Twenty years of p53 research: structural and functional aspects of the p53 protein". Oncogene. 18 (53): 7621–36. doi:10.1038/sj.onc.1203285. PMID 10618702.
↑  "OrthoMaM phylogenetic marker: TP53 coding sequence". Archived from the original on 2018-03-17. Retrieved 2009-12-02.
↑  Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM,  et al. (August 2009). "TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies". The Lancet. Oncology. 10 (8): 772–84. doi:10.1016/S1470-2045(09)70187-1. PMID 19625214.
↑  Sonoyama T, Sakai A, Mita Y, Yasuda Y, Kawamoto H, Yagi T, Yoshioka M, Mimura T, Nakachi K, Ouchida M, Yamamoto K, Shimizu K (2011). "TP53 codon 72 polymorphism is associated with pancreatic cancer risk in males, smokers and drinkers". Molecular Medicine Reports. 4 (3): 489–95. doi:10.3892/mmr.2011.449. PMID 21468597.
↑  Alawadi S, Ghabreau L, Alsaleh M, Abdulaziz Z, Rafeek M, Akil N, Alkhalaf M (September 2011). "P53 gene polymorphisms and breast cancer risk in Arab women". Medical Oncology. 28 (3): 709–15. doi:10.1007/s12032-010-9505-4. PMID 20443084. S2CID 207372095.
↑  Yu H, Huang YJ, Liu Z, Wang LE, Li G, Sturgis EM, Johnson DG, Wei Q (September 2011). "Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck". Molecular Carcinogenesis. 50 (9): 697–706. doi:10.1002/mc.20806. PMC 3142329. PMID 21656578.
↑  Piao JM, Kim HN, Song HR, Kweon SS, Choi JS, Yun WJ, Kim YC, Oh IJ, Kim KS, Shin MH (September 2011). "p53 codon 72 polymorphism and the risk of lung cancer in a Korean population". Lung Cancer. 73 (3): 264–7. doi:10.1016/j.lungcan.2010.12.017. PMID 21316118.
↑  Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Dong JH, Zhang L, Xu J, Shi W, Ren YC (November 2011). "TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis". Molecular Biology Reports. 38 (8): 4847–53. doi:10.1007/s11033-010-0619-8. PMID 21140221. S2CID 11730631.
↑  Jiang DK, Yao L, Ren WH, Wang WZ, Peng B, Yu L (December 2011). "TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis". Medical Oncology. 28 (4): 1129–35. doi:10.1007/s12032-010-9597-x. PMID 20552298. S2CID 32990396.
↑  Thurow HS, Haack R, Hartwig FP, Oliveira IO, Dellagostin OA, Gigante DP, Horta BL, Collares T, Seixas FK (December 2011). "TP53 gene polymorphism: importance to cancer, ethnicity and birth weight in a Brazilian cohort". Journal of Biosciences. 36 (5): 823–31. doi:10.1007/s12038-011-9147-5. PMID 22116280. S2CID 23027087.
↑  Huang CY, Su CT, Chu JS, Huang SP, Pu YS, Yang HY, Chung CJ, Wu CC, Hsueh YM (December 2011). "The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area". Toxicology and Applied Pharmacology. 257 (3): 349–55. doi:10.1016/j.taap.2011.09.018. PMID 21982800.